---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017880"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:25:48.092587+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q1 revenue $63M (down 95% YoY); net loss $140.9M; new CEO Marianne De Backer

## Summary
- Q1 2023 total revenues $63M vs $1.2B in Q1 2022 (-94.9%); net loss of $140.9M ($1.06/sh) vs net income of $518.6M.
- Cash, equivalents, and investments $2.3B at March 31; anticipates ~$272M payment to GSK in Q2 2023 for excess sotrovimab.
- Marianne De Backer joined as CEO in April 2023; Sung Lee appointed EVP & CFO in March 2023.
- Pipeline: Phase 2 data readouts for influenza (mid-2023), hepatitis B (2023), hepatitis D (H2 2023); $10M Gates Foundation grant for HIV vaccine trial.
- R&D expenses rose to $157.6M (up 75% YoY) driven by VIR-2482 influenza antibody program.

## SEC filing metadata
- accession: 0000950170-23-017880
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/0000950170-23-017880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/vir-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017880
- JSON: https://secwatch.observer/filing/0000950170-23-017880.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017880.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported first quarter ended March 31, 2023 results: revenue $63.0 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $63.0 million
  - Result: reported results
  source text: Total revenues for the quarter ended March 31, 2023, were $63.0 million compared to $1.2 billion for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/0000950170-23-017880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.